121 related articles for article (PubMed ID: 11996485)
21. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
22. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
23. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
24. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.
de Jong WK; Groen HJ; Koolen MG; Biesma B; Willems LN; Kwa HB; van Bochove A; van Tinteren H; Smit EF
Eur J Cancer; 2007 Nov; 43(16):2345-50. PubMed ID: 17826977
[TBL] [Abstract][Full Text] [Related]
25. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
26. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Jones SE; Khandelwal P; McIntyre K; Mennel R; Orr D; Kirby R; Agura E; Duncan L; Hyman W; Roque T; Regan D; Schuster M; Dimitrov N; Garrison L; Lange M
J Clin Oncol; 1999 Oct; 17(10):3025-32. PubMed ID: 10506596
[TBL] [Abstract][Full Text] [Related]
28. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.
Postmus PE; Scagliotti G; Groen HJ; Gozzelino F; Burghouts JT; Curran D; Sahmoud T; Kirkpatrick A; Giaccone G; Splinter TA
Eur J Cancer; 1996 Aug; 32A(9):1498-503. PubMed ID: 8911108
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
30. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
[TBL] [Abstract][Full Text] [Related]
31. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
Crawford J; Tomita DK; Mazanet R; Glaspy J; Ozer H
Cytokines Cell Mol Ther; 1999 Dec; 5(4):187-93. PubMed ID: 10850381
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
[TBL] [Abstract][Full Text] [Related]
33. A prospective randomised study in limited disease small cell carcinoma--doxorubicin and vincristine plus either cyclophosphamide or etoposide.
Abratt RP; Salton DG; Malan JR; Willcox PA
Eur J Cancer; 1995 Sep; 31A(10):1637-9. PubMed ID: 7488415
[TBL] [Abstract][Full Text] [Related]
34. Influence of age on the treatment of limited-stage small-cell lung cancer.
Siu LL; Shepherd FA; Murray N; Feld R; Pater J; Zee B
J Clin Oncol; 1996 Mar; 14(3):821-8. PubMed ID: 8622030
[TBL] [Abstract][Full Text] [Related]
35. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
[TBL] [Abstract][Full Text] [Related]
36. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group.
Lebeau B; Urban T; Bréchot JM; Paillotin D; Vincent J; Leclerc P; Meekel P; L'Her P; Lebas FX; Chastang C
Cancer; 1999 Oct; 86(8):1480-7. PubMed ID: 10526276
[TBL] [Abstract][Full Text] [Related]
37. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung.
de Jongh CA; Wade JC; Finley RS; Joshi JH; Aisner J; Wiernik PH; Schimpff SC
J Clin Oncol; 1983 May; 1(5):302-7. PubMed ID: 6321684
[TBL] [Abstract][Full Text] [Related]
38. The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working Party.
Thatcher N; Anderson H; Bleehen NM; Girling DJ; Lallemand G; Machin D; Stephens RJ
Eur J Cancer; 1995; 31A(2):152-6. PubMed ID: 7536433
[TBL] [Abstract][Full Text] [Related]
39. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
Bunn PA; Greco FA; Einhorn L
Semin Oncol; 1986 Sep; 13(3 Suppl 3):45-53. PubMed ID: 3020700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
